You are here

Biological Therapeutics

From patented antibodies to tumour-associated cell surface markers, we have a diverse portfolio of agents from pre-clinical to phase 1 clinical development available for collaborative development and/or licensing.

Peptides with excellent affinity and selectivity for ɑvß6 have been identified and characterised.

Read more

Pages